CD30 Imaging in Diffuse Large B-cell Lymphoma

Inclusion Criteria: * All patients with histologically proven CD30-positive (i.e. \> 1% cells) lymphomas who will be treated with BV, including: * HL * T-NHL * CTCL * DLBCL * Age ≥18 years * Signed written informed consent form (approved by the Institutional Review Board \[IRB\]/ Independent Ethics Committee \[IEC\]) obtained prior to any study specific screening procedures * Measurable disease: on CT scan at least 1 lesion/node with a long axis of \> 1.5 cm and at least one positive lesion on 18F-FDG PET scan * World Health Organization (WHO) performance status 0-2 (see appendix A) * Adequate hepatic function: total bilirubin ≤ 1.5 times upper limit of normal (ULN) (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome as defined by \> 80% unconjugated bilirubin) and Alanine Aminotransferase (ALAT) / Aspartate Aminotransferase (ASAT) ≤ 3 times ULN (unless due to lymphoma involvement of the liver; in that case ALAT/ASAT may be elevated up to 5 times ULN) * Adequate renal function: GFR \> 50 milliliter/ minute (ml/min) as estimated by the cockcroft \& gault formula at rehydration: Creatinine Clearance (CrCL) = (140-age \[in years\] x weight \[kg\] (x 0.85 for females) (0.815 x serum creatinine \[μmol/L\]) * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/liter (L) and platelet count ≥100 x 109/L, unless caused by diffuse bone marrow infiltration by lymphoma * Hemoglobin must be ≥ 8 g/dL (5.0 mmol/L), transfusion is allowed * Life expectancy of \>3 months with treatment * Negative pregnancy test at study entry, if applicable Exclusion Criteria: * Prior allergic reaction or known hypersensitivity to immunoglobulins, recombinant proteins, murine proteins, or to any excipient contained in the dug formulation of BV. * Peripheral sensory or motor neuropathy grade ≥ 2 * Patients with a serious psychiatric disorder that could, in the investigator's opinion, potentially interfere with the completion of treatment according to protocol * Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Claustrophobia to the extent that PET-CT is impossible * Pregnant or lactating women. Documentation of a negative pregnancy test must be available for pre-menopausal women with intact reproductive organs and for women less than two years after menopause